Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
Dr. Koppen will lead ElexoPharm’s preclinical drug discovery projects.

ElexoPharm GmbH has announced the appointment of Dr. Chris J. van Koppen as Head of Research.

He will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.

Dr. van Koppen holds a Ph.D. in Pharmacology and brings extensive industry experience in drug discovery.

Before joining ElexoPharm in January 2012, he served as Leader of four lead optimization projects at Merck Sharp & Dohme, The Netherlands.

He was responsible for delivery of candidate drugs for preclinical development in endocrinological diseases.

Dr. van Koppen was also strongly involved in assay development, HTS, lead finding and proof-of-concept projects.

Before working at MSD, Dr. van Koppen was independent group leader at the Universitätsklinikum Essen and received his Habilitation in Pharmacology and Toxicology.

He has published almost 70 peer-reviewed research papers, including publications in high IF journals (J Biol Chem, Endocrinology, J Clin Endocrinol Metab, PNAS, Mol Pharmacol, Br J Pharmacol, Thorax, Pharmacol Ther, and EMBO Journal).

Axel Koch, Managing Director of ElexoPharm, said: “We are delighted to have such an experienced scientist as Head of Research. His expertise in successfully leading preclinical drug discovery projects will strongly advance our innovative portfolio.”

Dr. van Koppen adds: “I am thrilled to work in the dynamic team of ElexoPharm on highly innovative projects to design and develop drugs for the treatment of endocrinological, cardiovascular and neoplastic diseases.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ElexoPharm GmbH Receives ETB Grant
EuroTransBio grant of €1.5 million for tumor vessel targeting program ('Small Mol Act').
Thursday, October 18, 2012
ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
Dr. Koppen will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.
Monday, April 16, 2012
Scientific News
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!